Wainua (Eplontersen)
Productby Ionis Pharmaceuticals and AstraZeneca
Heard in 1 episode across 1 show since Jul 2026
Wainua (eplontersen) is a prescription medication used for the treatment of polyneuropathy caused by hereditary transthyretin-mediated amyloidosis (hATTR) in adults. Developed by Ionis Pharmaceuticals and AstraZeneca, it is a transthyretin-directed antisense oligonucleotide designed to reduce the production of mutant and wild-type TTR protein.
Episodes
First heard
Expert statements
Episodes per month
Public PodLume episodes featuring it, over the last year.
Show the data
| Month | Episodes |
|---|---|
| Nov 2025 | 0 |
| Dec 2025 | 0 |
| Jan 2026 | 0 |
| Feb 2026 | 0 |
| Mar 2026 | 0 |
| Apr 2026 | 0 |
| May 2026 | 0 |
| Jun 2026 | 0 |
| Jul 2026 | 1 |
| Aug 2026 | 0 |
| Sep 2026 | 0 |
| Oct 2026 | 0 |
What experts have said about Wainua (Eplontersen)
2 statements · 1 positive · 1 negative
Wainua failed to reduce cardiovascular events or related deaths.
“Wainua did not manage to do that and to reduce cardiovascular events or death related to heart problems”
Open the episode · Deutz Buy, Astrazeneca's Trial, Computacenter UpListen at 3:03
A successful Wainua trial could have generated billions in additional sales.
“a successful trial could have led to billions of dollars more in sales”
Open the episode · Deutz Buy, Astrazeneca's Trial, Computacenter UpListen at 3:15
Statements are attributed to the speaker as said on the episode and reflect their view at the time, not PodLume's. They are not advice.
Episodes
1 episode featuring Wainua (Eplontersen), newest first
